

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2019/141549 A9

(43) International Publication Date
25 July 2019 (25.07.2019)

(51) International Patent Classification:

C07D 487/10 (2006.01) A61P 35/00 (2006.01)
A61K 31/407 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/EP2019/050370

(22) International Filing Date:

09 January 2019 (09.01.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18461506.0 16 January 2018 (16.01.2018) EP

(71) Applicant: **ADAMED PHARMA S.A.** [PL/PL]; Mariana
Adamkiewiczza 6A, Pienkow, 05-152 Czosnow (PL).

(72) Inventors: **FEDER, Marcin**; ul. Obroncow Tobruku
19/118, 01-494 Warszawa (PL). **MAZUR, Maria**; ul.
Generala Sylwestra Kaliskiego 45/161, 01-476 Warsza-
wa (PL). **KALINOWSKA, Iwona**; ul. Skalskiego 3/27,
03-982 Warszawa (PL). **JASZCZEWSKA, Joanna**; ul.
Gen. Ludomila Rayskiego 3/69, 01-307 Warszawa (PL).
LEWANDOWSKI, Wojciech; ul. Basniowa 3, 05-600
Grojec (PL). **WITKOWSKI, Jakub**; ul. Odkryta 65E/10,
03-140 Warszawa (PL). **JELEN, Sabina**; ul. Rudnickiego
10A/3, 01-858 Warszawa (PL). **WOS-LATOSI, Katarzy-
na**; ul. Koscielna Droga 117, 05-092 Lomianki (PL).

(74) Agent: **SULIKOWSKI, Daniel**; ADMARKA SP. Z O.O.,
Ul. Mariana Adamkiewiczza 6, Pienkow, 05-152 Czosnow
(PL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(48) Date of publication of this corrected version:


10 October 2019 (10.10.2019)

(15) Information about Correction:

see Notice of 10 October 2019 (10.10.2019)

WO 2019/141549 A9

(54) Title: 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS
THERAPEUTIC AGENTS ACTIVATING TP53



Formula (I)

(57) Abstract: The invention relates to 1,2,3',5'- tetrahydro- 2H- spiro[n-
dole- 3,1' - pyrrolo[3,4- c]pyrrole]- 2,3'- dione compounds represented by
formula (I), wherein all symbols and variables are as defined in the descrip-
tion. The compounds can find use in a method of prevention and/or treat-
ment of diseases selected from the group consisting of cancer, immune dis-
eases, inflammatory conditions, allergic skin diseases associated with exces-
sive proliferation, blinding disease and viral infections.